123 related articles for article (PubMed ID: 10637824)
1. Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges.
McCance-Katz E; Sevarino K; Gottschalk PC; Kosten T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Oct; 19(4):159-86. PubMed ID: 10637824
[TBL] [Abstract][Full Text] [Related]
2. Cocaine addiction as a neurological disorder: implications for treatment.
Majewska MD
NIDA Res Monogr; 1996; 163():1-26. PubMed ID: 8809851
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cocaine abuse: pharmacotherapy.
Kleber HD
Ciba Found Symp; 1992; 166():195-200; discussion 200-6. PubMed ID: 1638913
[TBL] [Abstract][Full Text] [Related]
4. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development.
Platt DM; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2002 Oct; 163(3-4):265-82. PubMed ID: 12373428
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects.
Carroll FI; Howell LL; Kuhar MJ
J Med Chem; 1999 Jul; 42(15):2721-36. PubMed ID: 10425082
[No Abstract] [Full Text] [Related]
6. Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development.
Sevarino KA; Oliveto A; Kosten TR
Ann N Y Acad Sci; 2000; 909():51-87. PubMed ID: 10911924
[TBL] [Abstract][Full Text] [Related]
7. Agents in development for the management of cocaine abuse.
Gorelick DA; Gardner EL; Xi ZX
Drugs; 2004; 64(14):1547-73. PubMed ID: 15233592
[TBL] [Abstract][Full Text] [Related]
8. Vanoxerine National Institute on Drug Abuse.
Preti A
Curr Opin Investig Drugs; 2000 Oct; 1(2):241-51. PubMed ID: 11249581
[TBL] [Abstract][Full Text] [Related]
9. D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action.
Hummel M; Unterwald EM
J Cell Physiol; 2002 Apr; 191(1):17-27. PubMed ID: 11920678
[TBL] [Abstract][Full Text] [Related]
10. Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects.
Carey RJ; DePalma G; Damianopoulos E; Shanahan A; Müller CP; Huston JP
Brain Res; 2005 Feb; 1034(1-2):162-71. PubMed ID: 15713268
[TBL] [Abstract][Full Text] [Related]
11. [Cocaine and crack addiction: a growing public health problem].
Haas C; Karila L; Lowenstein W
Bull Acad Natl Med; 2009 Apr; 193(4):947-62; discussion 962-3. PubMed ID: 20120283
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of cerebral ischemia in cocaine dependence.
Kosten TR
Drug Alcohol Depend; 1998 Jan; 49(2):133-44. PubMed ID: 9543650
[TBL] [Abstract][Full Text] [Related]
13. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
Cao J; Kulkarni SS; Husbands SM; Bowen WD; Williams W; Kopajtic T; Katz JL; George C; Newman AH
J Med Chem; 2003 Jun; 46(13):2589-98. PubMed ID: 12801223
[TBL] [Abstract][Full Text] [Related]
14. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
Rothman RB; Blough BE; Woolverton WL; Anderson KG; Negus SS; Mello NK; Roth BL; Baumann MH
J Pharmacol Exp Ther; 2005 Jun; 313(3):1361-9. PubMed ID: 15761112
[TBL] [Abstract][Full Text] [Related]
15. Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice.
Nakamura S; Ago Y; Hayashi A; Itoh S; Kakuda M; Hashimoto H; Baba A; Matsuda T
Synapse; 2006 Dec; 60(7):479-84. PubMed ID: 16952156
[TBL] [Abstract][Full Text] [Related]
16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
17. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
18. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging.
Lindsey KP; Wilcox KM; Votaw JR; Goodman MM; Plisson C; Carroll FI; Rice KC; Howell LL
J Pharmacol Exp Ther; 2004 Jun; 309(3):959-69. PubMed ID: 14982963
[TBL] [Abstract][Full Text] [Related]
19. New developments in the pharmacotherapy of cocaine abuse.
Preti A
Addict Biol; 2007 Jun; 12(2):133-51. PubMed ID: 17508985
[TBL] [Abstract][Full Text] [Related]
20. Rapid regulation of the dopamine transporter: role in stimulant addiction?
Zahniser NR; Sorkin A
Neuropharmacology; 2004; 47 Suppl 1():80-91. PubMed ID: 15464127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
